Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: Results from ALL-BFM 90 and 95

Journal of Clinical Oncology

Volumn 24, Issue 36, 2006, Pages 5742-5749

  Schrauder, André ^b   Reiter, Alfred ^b   Gadner, Helmut ^b   Niethammer, Dietrich ^b   Klingebiel, Thomas ^b   Kremens, Bernhard ^b   Peters, Christina ^b   Ebell, Wolfram ^b   Zimmermann, Martin ^b   Niggli, Felix ^b   Ludwig, Wolf Dieter ^b   Riehm, Hansjörg ^b   Welte, Karl ^b   Schrappe, Martin ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; THYMOCYTE ANTIBODY; TIOGUANINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIBLING; SINGLE DRUG DOSE; T CELL LEUKEMIA; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOTRANSPLANTATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; INFANT; MULTICENTER STUDY; NEWBORN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, T-CELL, ACUTE; MALE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34247399924     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.2679     Document Type: Article

References (58)

1. Schrappe M, Camitta B, Pui CH, et al: Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 14:2193-2194, 2000
2. Pui CH, Boyett JM, Rivera GK, et al: Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 14:2286-2294, 2000
3. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90 - German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322, 2000
4. Riehm H, Reiter A, Schrappe M, et al: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 199:151-160, 1987
5. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
6. Kersey JH: Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90: 4243-4251, 1997
7. Schrappe M, Beier R, Burger B: New treatment strategies in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15:729-740, 2002
8. Pui CH, Benin FG, Crist WM: Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82: 343-362, 1993
9. Chessels JM, Swansbury GJ, Reeves B, et al: Cytogenetics and prognosis in childhood lymphoblastic leukaemia: Results of MRC UKALL X - Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 99:93-100, 1997
10. Eden OB: Acute lymphoblastic leukaemia: Whom and when should we transplant? Pediatr Transplant 3:108-115, 1999 (suppl 1)
11. Hahn T, Wall D, Camitta B, et al: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 11:823-861, 2005
12. Wheeler K, Richards S, Bailey C, et al: Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: The MRC UKALL X experience - Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 101:94-103, 1998
13. Boulad F, Steinherz P, Reyes B, et al: Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: A single-institution study. J Clin Oncol 17:197-207, 1999
14. Borgmann A, von Stackelberg A, Hartmann R, et al: Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 101:3835-3839, 2003
15. Wheeler KA, Richards SM, Bailey CC, et al: Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: Results from Medical Research Council UKALL X and XI. Blood 96:2412-2418, 2000
16. Balduzzi A, Valsecchi MG, Uderzo C, et al: Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study. Lancet 366:635-642, 2005
17. Arico M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998-1006, 2000
18. Schrappe M, Arico M, Harbott J, et al: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92:2730-2741, 1998
19. Pui CH, Gaynon PS, Boyett JM, et al: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915, 2002
20. Schrappe M, Reiter A, Zimmermann M, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995: Berlin-Frankfurt-Munster. Leukemia 14:2205-2222, 2000
21. Schrappe M, Stanulla M: Treatment of childhood acute lymphoblastic leukemia, in Pui CH (ed): Treatment of Acute Leukemias. Totowa, NJ, Humana Press Inc, 2003, pp 87-104
22. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
23. van Spaceder Does-van den Berg A, Bartram CR, Basso G, et al: Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. Med Pediatr Oncol 20:497-505, 1992
24. Bene MC, Castoldi G, Knapp W, et al: Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9:1783-1786, 1995
25. Ludwig WD, Rieder H, Bartram CR, et al: Immunophenotypic and genotyplc features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood 92:1898-1909, 1998
26. Harbott J, Ritterbach J, Ludwig WD, et al: Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: Experience of the BFM trials. Recent Results Cancer Res 131:123-132, 1993
27. Schlieben S, Borkhardt A, Reinisch I, et al: Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 10:957-963, 1996
28. Viehmann S, Borkhardt A, Lampert F, et al: Multiplex PCR: A rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia. Ann Hematol 78:157-162, 1999
29. Langermann HJ, Henze G, Wulf M, et al: Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: Prognostic significance and practical application. Klin Padiatr 194:209-213, 1982
30. Welte K, Reiter A, Mempel K, et al: A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: Berlin-Frankfurt-Munster Study Group. Blood 87: 3143-3150, 1996
31. Dopfer R, Henze G, Bender-Gotze C, et al: Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: Results of the German Cooperative Study. Blood 78: 2780-2784, 1991
32. Niethammer D, Klingebiel T, Riehm H, et al: Role and perspectives of BMT in ALL: The BFM experience. Bone Marrow Transplant 7:14-18, 1991 (suppl 3)
33. Handgretinger R, Schumm M, Lang P, et al: Transplantation of megadoses of purified haploidentical stem cells. Ann NY Acad Sci 872:351-361, 1999
34. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
35. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
36. Lang P, Handgretinger R, Niethammer D, et al: Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood 101:1630-1636, 2003
37. Bordigoni P, Vernant JP, Souillet G, et al: Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: A cooperative study of the Groupe d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 7:747-753, 1989
38. Barrett AJ, Horowitz MM, Gale RP, et al: Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 74:862-871, 1989
39. Wingard JR, Piantadosi S, Santos GW, et al: Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol 8:820-830, 1990
40. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100, 2002
41. Farag SS, Fehniger T, Ruggeri L, et al: Natural killer cells: Biology and application in stem-cell transplantation. Cytotherapy 4:445-446, 2002
42. Farag SS, Fehniger TA, Ruggeri L, et al: Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 100: 1935-1947, 2002
43. Fabre JW: The allogeneic response and tumor immunity. Nat Med 7:649-652, 2001
44. Bunin N, Carston M, Wall D, et al: Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 99:3151-3157, 2002
45. Balduzzi A, Valsecchi MG, Silvestri D, et al: Transplant-related toxicity and mortality: An AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant 29:93-100, 2002
46. Locatelli F, Zecca M, Messina C, et al: Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 16: 2228-2237, 2002
47. Flomenberg N, Baxter-Lowe LA, Confer D, et al: Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104: 1923-1930, 2004
48. Petersdorf EW, Anasetti C, Martin PJ, et al: Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104:2976-2980, 2004
49. Matthes-Martin S, Lion T, Aberle SW, et al: Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: The impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 31:803-808, 2003
50. Teramura T, Naya M, Yoshihara T, et al: Adenoviral infection in hematopoietic stem cell transplantation: Early diagnosis with quantitative detection of the viral genome in serum and urine. Bone Marrow Transplant 33:87-92, 2004
51. Lion T, Baumgartinger R, Watzinger F, et al: Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102:1114-1120, 2003
52. Peters C, Minkov M, Gadner H, et al: Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 26:405-411, 2000
53. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731-1738, 1998
54. Willemse MJ, Seriu T, Hettinger K, et al: Detection of minimal residual disease identifies differences in treatment response betweer T-ALL and precursor B-ALL. Blood 99:4386-4393 2002
55. Goulden N, Bader P, van der Velden V, et al Minimal residual disease prior to stem cell transplan for childhood acute lymphoblastic leukaemia. Br J Haematol 122:24-29, 2003
56. Bader P, Hancock J, Kreyenberg H, et al: Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16:1668-1672, 2002
57. Krejci O, van der Velden V, Bader P, et al: Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: A report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 32:849-851, 2003
58. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998